Novartis and Molecular Partners Initiate P-II/III EMPATHY Study to Evaluate Ensovibep (MP0420) for the Treatment of COVID-19

 Novartis and Molecular Partners Initiate P-II/III EMPATHY Study to Evaluate Ensovibep (MP0420) for the Treatment of COVID-19

Shots:

  • The P-II/II EMPATHY study will evaluate the safety & efficacy of ensovibep in patients with COVID-19, who are in the early stages of infection, to prevent worsening symptoms and hospitalization. The P-II study will enroll 400 patients in the P-II part to identify dose, with anticipated results in Aug’2021
  • P-III part will be conducted with additional 1,700 patients, with expected results in H1’21. Novartis will lead the clinical program for ensovibep while Molecular Partners will sponsor the studies
  • If EMPATHY results are positive, Novartis is planning to seek the FDA’s EUA for the DARPin therapeutic candidate

Click here to­ read full press release/ article | Ref: Novartis | Image: Clinical Trials Arena

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post